These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11361484)

  • 1. Issues in the design of clinical trials for safety in HIV-infected children.
    Lindsey JC; Kline MW
    Pediatr AIDS HIV Infect; 1996 Apr; 7(2):69-82. PubMed ID: 11361484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trials in children--How are they implemented?
    Hirtz DG; Gilbert PR; Terrill CM; Buckman SY
    Pediatr Neurol; 2006 Jun; 34(6):436-8. PubMed ID: 16765820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New FDA rules force drug makers to detail youth-specific effects. Food and Drug Administration.
    Newsline People AIDS Coalit N Y; 1999 Jan; ():34. PubMed ID: 11367188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Criteria supporting the study of drugs in the newborn.
    Ward RM; Benitz WE; Benjamin DK; Blackmon L; Giacoia GP; Hudak M; Lasky T; Rodriguez W; Selen A
    Clin Ther; 2006 Sep; 28(9):1385-98. PubMed ID: 17062311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
    Glasser SP; Salas M; Delzell E
    J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scientific and ethical considerations in trial design for investigational agents for the treatment of human immunodeficiency virus infection.
    Feinberg J; Japour AJ
    Clin Infect Dis; 2003 Jan; 36(2):201-6. PubMed ID: 12522753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA explores new antiretroviral trial designs: interview with David Feigal, M.D. Interview by John S. James.
    Feigal D
    AIDS Treat News; 1997 Jun; (No 273):1-5. PubMed ID: 11364399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Some design issues in trials of microbicides for the prevention of HIV infection.
    Fleming TR; Richardson BA
    J Infect Dis; 2004 Aug; 190(4):666-74. PubMed ID: 15272392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug studies for children and adults.
    Vazquez E
    Posit Aware; 1998; 9(3):15-6. PubMed ID: 11365482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA evaluates accelerated approval process. Food and Drug Administration.
    Common Factor; 1995 Apr; (no 10):18. PubMed ID: 11362343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International Conference on Harmonisation; choice of control group and related issues in clinical trials; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2001 May; 66(93):24390-1. PubMed ID: 12356096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Children on losing end of access to new drugs.
    AIDS Alert; 1998 Jan; 13(1):10-2. PubMed ID: 11364862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA clarifies rules, allows combining antiretrovirals in clinical trials. Food and Drug Administration.
    AIDS Treat News; 1999 Nov; (No 331):5-6. PubMed ID: 11367127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.
    Wainberg MA; Sawyer JP; Montaner JS; Murphy RL; Kuritzkes DR; Raffi F
    Antivir Ther; 2005; 10(1):13-28. PubMed ID: 15751760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnostic kits in parasitology: which controls?].
    Rossi P
    Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selected Proceedings of the NICHD/FDA newborn drug development initiative: Part II.
    Giacoia GP; Mattison DR
    Clin Ther; 2006 Sep; 28(9):1337-41. PubMed ID: 17062307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IRB/FDA requirements relevant to HIV/AIDS clinical trials in correctional settings.
    Cohen J;
    AIDS Read; 2001 Jan; 11(1):41-2. PubMed ID: 11215087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analyses and adaptive group sequential designs in the clinical development process.
    Jennison C; Turnbull BW
    J Biopharm Stat; 2005; 15(4):537-58. PubMed ID: 16022162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.
    Sáez-Llorens X; Violari A; Deetz CO; Rode RA; Gomez P; Handelsman E; Pelton S; Ramilo O; Cahn P; Chadwick E; Allen U; Arpadi S; Castrejón MM; Heuser RS; Kempf DJ; Bertz RJ; Hsu AF; Bernstein B; Renz CL; Sun E
    Pediatr Infect Dis J; 2003 Mar; 22(3):216-24. PubMed ID: 12634581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.